Liver disease drug trial pulled before it began
NCT ID NCT02900183
First seen Dec 26, 2025 · Last updated May 22, 2026 · Updated 21 times
Summary
This study was designed to test the safety and effects of a drug called ARC-AAT in people with Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can cause liver and lung disease. Participants would have received multiple doses and needed liver biopsies before and after treatment. However, the trial was withdrawn before any volunteers were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site 1
Toronto, Ontario, M5T3A9, Canada
-
Research Site 2
Dublin, Ireland
-
Research Site 3
Pavia, 27100, Italy
-
Research Site 4
Malmö, SE-205 02, Sweden
Conditions
Explore the condition pages connected to this study.